全文获取类型
收费全文 | 1182篇 |
免费 | 84篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 32篇 |
妇产科学 | 15篇 |
基础医学 | 154篇 |
口腔科学 | 44篇 |
临床医学 | 126篇 |
内科学 | 300篇 |
皮肤病学 | 25篇 |
神经病学 | 53篇 |
特种医学 | 43篇 |
外科学 | 79篇 |
综合类 | 26篇 |
预防医学 | 145篇 |
眼科学 | 16篇 |
药学 | 47篇 |
肿瘤学 | 160篇 |
出版年
2023年 | 7篇 |
2022年 | 13篇 |
2021年 | 21篇 |
2020年 | 7篇 |
2019年 | 16篇 |
2018年 | 19篇 |
2017年 | 16篇 |
2016年 | 12篇 |
2015年 | 18篇 |
2014年 | 31篇 |
2013年 | 52篇 |
2012年 | 57篇 |
2011年 | 78篇 |
2010年 | 43篇 |
2009年 | 34篇 |
2008年 | 71篇 |
2007年 | 69篇 |
2006年 | 61篇 |
2005年 | 69篇 |
2004年 | 51篇 |
2003年 | 61篇 |
2002年 | 53篇 |
2001年 | 39篇 |
2000年 | 41篇 |
1999年 | 25篇 |
1998年 | 13篇 |
1997年 | 20篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 8篇 |
1992年 | 16篇 |
1991年 | 21篇 |
1990年 | 19篇 |
1989年 | 13篇 |
1988年 | 18篇 |
1987年 | 16篇 |
1986年 | 16篇 |
1985年 | 20篇 |
1984年 | 14篇 |
1983年 | 11篇 |
1982年 | 4篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1979年 | 8篇 |
1978年 | 11篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1972年 | 5篇 |
1956年 | 4篇 |
排序方式: 共有1271条查询结果,搜索用时 24 毫秒
41.
42.
Javed Butler Mihai Gheorghiade Anita Kelkar Gregg C. Fonarow Stefan Anker Stephen J. Greene Lampros Papadimitriou Sean Collins Frank Ruschitzka Clyde W. Yancy John R. Teerlink Kirkwood Adams Gadi Cotter Piotr Ponikowski G. Michael Felker Marco Metra Gerasimos Filippatos 《European journal of heart failure》2015,17(11):1104-1113
Acute worsening heart failure (WHF) is seen in a sizable portion of patients hospitalized for heart failure, and is increasingly being recognized as an entity that is associated with an adverse in‐hospital course. WHF is generally defined as worsening heart failure symptoms and signs requiring an intensification of therapy, and is reported to be seen in anywhere from 5% to 42% of heart failure admissions. It is difficult to ascertain the exact epidemiology of WHF due to varying definitions used in the literature. Studies indicate that WHF cannot be precisely predicted on the basis of baseline variables assessed at the time of admission. Recent data suggest that some experimental therapies may reduce the risk of development of WHF among hospitalized heart failure patients, and this is associated with a reduction in risk of subsequent post‐discharge cardiovascular mortality. In this respect, WHF holds promise as a endpoint for acute heart failure clinical trials to better elucidate the benefit of targeted novel therapies. Better understanding of the pathophysiology and a consensus on the definition of WHF will further improve our epidemiological and clinical understanding of this entity. 相似文献
43.
Ornella Pagliano Robert M. Morrison Joe-Marc Chauvin Hridesh Banerjee Diwakar Davar Quanquan Ding Tokiyoshi Tanegashima Wentao Gao Saranya R. Chakka Richelle DeBlasio Ava Lowin Kevin Kara Mignane Ka Bochra Zidi Rada Amin Itay Raphael Shuowen Zhang Simon C. Watkins Cindy Sander John M. Kirkwood Marcus Bosenberg Ana C. Anderson Vijay K. Kuchroo Lawrence P. Kane Alan J. Korman Arvind Rajpal Sean M. West Minhua Han Christine Bee Xiaodi Deng Xiao Min Schebye Pavel Strop Hassane M. Zarour 《The Journal of clinical investigation》2022,132(9)
T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) negatively regulates innate and adaptive immunity in cancer. To identify the mechanisms of Tim-3 in cancer immunity, we evaluated the effects of Tim-3 blockade in human and mouse melanoma. Here, we show that human programmed cell death 1–positive (PD-1+) Tim-3+CD8+ tumor-infiltrating lymphocytes (TILs) upregulate phosphatidylserine (PS), a receptor for Tim-3, and acquire cell surface myeloid markers from antigen-presenting cells (APCs) through transfer of membrane fragments called trogocytosis. Tim-3 blockade acted on Tim-3+ APCs in a PS-dependent fashion to disrupt the trogocytosis of activated tumor antigen–specific CD8+ T cells and PD-1+Tim-3+ CD8+ TILs isolated from patients with melanoma. Tim-3 and PD-1 blockades cooperated to disrupt trogocytosis of CD8+ TILs in 2 melanoma mouse models, decreasing tumor burden and prolonging survival. Deleting Tim-3 in dendritic cells but not in CD8+ T cells impeded the trogocytosis of CD8+ TILs in vivo. Trogocytosed CD8+ T cells presented tumor peptide–major histocompatibility complexes and became the target of fratricide T cell killing, which was reversed by Tim-3 blockade. Our findings have uncovered a mechanism Tim-3 uses to limit antitumor immunity. 相似文献
44.
Armin Rashidi Thomas B.L. Kirkwood Daryl P. Shanley 《Mechanisms of ageing and development》2009,130(4):216-221
The lack of an effective antioxidant system in beta-cells, which renders them susceptible to oxidative stress, is to date without explanation. The particular weakness of beta-cells in females, in both humans and mice, is another unexplained observation. We hypothesise that reactive oxygen species (ROS) in beta-cells, by their negative effect on insulin synthesis/secretion, play a fitness-enhancing role for the whole organism. Under stress conditions, the release of stress hormones produces insulin resistance and, owing to ROS preventing beta-cells from secreting insulin at the level required to maintain homeostasis, diverts glucose to insulin-independent tissues such as the brain and the foetus. We suggest that pancreatic beta-cells lost part of their antioxidant defence in association with brain evolution, and lost even more in females when placental mammals evolved. The unusual antioxidant status of beta-cells may thus be explained as an instance of co-evolution of the brain, cortisol and corticosteroid receptors, and beta-cells in the endocrine pancreas. 相似文献
45.
46.
47.
48.
Zoya R Yurkovetsky John M Kirkwood Howard D Edington Adele M Marrangoni Lyudmila Velikokhatnaya Matthew T Winans Elieser Gorelik Anna E Lokshin 《Clinical cancer research》2007,13(8):2422-2428
PURPOSE: Interferon (IFN)-alpha2b is the only Food and Drug Administration-approved treatment for operable high-risk melanoma that has been shown to significantly and durably prolong relapse-free survival (RFS) of patients with stage IIB-III melanoma. Development of reliable serum assays may contribute to the development of methods for earlier detection of melanoma and the selection of patients who may be most susceptible to current available interventions with IFNalpha. EXPERIMENTAL DESIGN: A powerful high-throughput xMAP multiplex immunobead assay technology (Luminex Corp., Austin, TX) was used to simultaneously test 29 cytokines, chemokines, angiogenic as well as growth factors, and soluble receptors in the sera of 179 patients with high-risk melanoma and 378 healthy individuals. RESULTS: Serum concentrations of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-8, IL-12p40, IL-13, granulocyte colony-stimulating factor, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, IFNalpha, tumor necrosis factor (TNF)-alpha, epidermal growth factor, vascular endothelial growth factor (VEGF), and TNF receptor II were found to be significantly higher in patients with resected high-risk melanoma compared with healthy controls. Bayesian Network algorithm classification of the data offered 90% sensitivity at 98% specificity with 96.5% of melanoma patients distinguished from healthy individuals. IFN-alpha2b therapy resulted in a significant decrease of serum levels of immunosuppressive and tumor angiogenic/growth stimulatory factors (VEGF, epidermal growth factor, and hepatocyte growth factor) and increased levels of antiangiogenic IFN-gamma inducible protein 10 (IP-10) and IFN-alpha. Pretreatment levels of proinflammatory cytokines IL-1beta, IL-1alpha, IL-6, TNF-alpha, and chemokines MIP-1alpha and MIP-1beta were found to be significantly higher in the serum of patients with longer RFS values of 1 to 5 and >5 years when compared with patients with shorter RFS of <1 year. CONCLUSION: These data show that multiplexed analysis of serum biomarkers is useful for the evaluation of prognostic markers of clinical outcome and potential predictive markers of response to IFN-alpha2b in patients with high-risk operable melanoma. 相似文献
49.
Michael J Robertson John M Kirkwood Theodore F Logan Kevin M Koch Steven Kathman Lyndon C Kirby William N Bell Linda M Thurmond Jill Weisenbach Mohammed M Dar 《Clinical cancer research》2008,14(11):3462-3469
PURPOSE: Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. A phase I study of recombinant human IL-18 (rhIL-18) was done to determine the toxicity, pharmacokinetics, and biological activities of rhIL-18 administered at different doses in two different schedules to patients with advanced cancer. EXPERIMENTAL DESIGN: Cohorts of three to four patients were given escalating doses of rhIL-18 as a 2-h i.v. infusion either on 5 consecutive days repeated every 28 days (group A) or once a week (group B) for up to 6 months. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic measurements. RESULTS: Nineteen patients (10 melanoma and 9 renal cell cancer) were given rhIL-18 in doses of 100, 500, or 1,000 microg/kg (group A) or 100, 1,000, or 2,000 microg/kg (group B). Common side effects included chills, fever, headache, fatigue, and nausea. Common laboratory abnormalities included transient, asymptomatic grade 1 to 3 lymphopenia, grade 1 to 4 hyperglycemia, grade 1 to 2 anemia, neutropenia, hypoalbuminemia, liver enzyme elevations, and serum creatinine elevations. No dose-limiting toxicities were observed. Biological effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-gamma, granulocyte macrophage colony-stimulating factor, and IL-18-binding protein were observed following dosing. CONCLUSIONS: rhIL-18 can be given in biologically active doses by either weekly infusions or daily infusions for 5 days repeated every 28 days to patients with advanced cancer. Toxicity was generally mild to moderate, and a maximum tolerated dose of rhIL-18 by either schedule was not determined. 相似文献
50.